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Objective: The DahlS.Z-Lepr
fa/Lepr
fa (DS/obese) rat strain was established from a cross between Dahl salt-sensitive rats and
Zucker fatty (fa/fa) rats, the latter of which harbor a missense mutation in the leptin receptor gene (Lepr). We examined whether
DS/obese rats might be a suitable animal model of metabolic syndrome in humans.
Methods: The systemic pathophysiological and metabolic characteristics of DS/obese rats were determined and compared with
those of homozygous lean littermates, namely, DahlS.Z-Lepr
þ/Lepr
þ (DS/lean) rats.
Results: Systolic blood pressure was higher in DS/obese rats fed a normal diet than in DS/lean rats at 11 weeks of age and
thereafter. The survival rate of DS/obese rats was significantly lower than that of DS/lean rats at 18 weeks. Body weight, visceral
and subcutaneous fat mass, as well as heart, kidney and liver weights, were increased in DS/obese rats at 18 weeks compared
with DS/lean rats. Serum low-density lipoprotein (LDL)-cholesterol, triglyceride and insulin concentrations, as well as the ratio of
LDL-cholesterol to high-density lipoprotein-cholesterol levels, were increased in DS/obese rats, whereas serum glucose
concentration did not differ significantly between DS/obese and DS/lean rats. Creatinine clearance was decreased and urinary
protein content was increased in DS/obese rats, which also manifested lipid accumulation in the liver and elevation of serum
alanine aminotransferase levels.
Conclusion: These results show that the phenotype of DS/obese rats is similar to that of humans with metabolic syndrome, and
that these animals may thus be an appropriate model for this condition.
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Introduction
The combination of insulin resistance, glucose intolerance,
dyslipidemia, hypertension and obesity, in particular abdo-
minal obesity, has been referred to as metabolic syndrome
(MetS), the prevalence of which is increasing worldwide as
a result of changes in diet and lifestyle. Individuals with
MetS are at increased risk for development of diabetes and
cardiovascular disease.
1,2
Given that MetS is a multifactorial condition, it has been
difficult to establish adequate experimental models for its
study. The most representative rat strain available to date for
the study of MetS is thought to be the Zucker fatty (fa/fa)
rat,
3 which harbors a missense mutation (A to C at
nucleotide 806) in the gene for the leptin receptor that
results in a Gln269Pro substitution in the extracellular
domain common to all receptor isoforms.
4 This mutation
is associated with reduced binding of leptin to the surface of
receptor-expressing cells, without a change in the affinity
constant for leptin, and with the development of leptin
resistance in the brain, leading to hyperphagia, physical
inactivity and consequent obesity. However, conflicting data
have been presented with regard to whether these animals
are hypertensive compared with lean controls.
3 Leptin
receptor mutations have been detected in humans with
severe, early-onset obesity.
5
The Dahl salt-sensitive (DS) rat is one of the most widely
studied animal models of hypertension. DS rats develop
salt-induced hypertension and subsequently manifest a
clear transition from cardiac hypertrophy to heart failure.
6
We previously characterized early changes in excitation–
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rats.
7 The value of these animals for investigations into the
pharmacology and pathophysiology of hypertension and
cardiovascular disease has been recognized for many years.
Indeed, we have examined the effects of various drugs and
other interventions on cardiac pathophysiology in this
model of hypertension and heart failure.
8–12
We have now evaluated a potential new animal model of
MetS, the DahlS.Z-Lepr
fa/Lepr
fa (DS/obese) rat, which was
established by crossing DS rats and Zucker rats with the
missense mutation in the leptin receptor gene (Lepr). We
examined the systemic pathophysiology and metabolic
changes in DS/obese rats in comparison with their lean
littermates, DahlS.Z-Lepr
þ/Lepr
þ (DS/lean) rats, in order to
validate their suitability as an animal model of MetS.
Materials and methods
Derivation and genetic characterization of DS/obese rats
DahlS.Z-Lepr
fa/Slc rats were generated as the result of an
initial mating of a male Zucker rat (Japan SLC, Hamamatsu,
Japan) heterozygous for the fa allele of Lepr with a female
DahlS/Jr Sea rat (Seac Yoshitomi, Fukuoka, Japan), followed
by multiple rounds of backcrossing of the resulting progeny
to the DS strain.
13 The fa locus was genotyped by polymerase
chain reaction-restricted fragment length polymorphism
assay as follows. A primer set to detect the fa allele was
designed to cover a 111-bp region containing the fa muta-
tion site in the Lepr with the following sequences: 50-TATGG
AAGTCACAGATGATGG-30 and 50-CTTACGATTGTAGAATTC
TCTAA-30. The MspI digestion of the fa allele produces two
fragments of 78 and 33bp. In each generation, male rats in
which the fa allele was detected were selected in back-
crossing to produce the subsequent generation. Eight to
twelve backcrosses were performed to eliminate the unde-
sired genes of the Zucker strain. The final congenic strain was
generated by M Nishimura and M Mori (Hamamatsu
University School of Medicine) and was established under
specific pathogen-free conditions by Japan SLC. Mating of
heterozygotes yielded three genotypes but only two pheno-
types: homozygous (fa/fa) obese, heterozygous (fa/þ) lean
and homozygous (þ/þ) lean, in the ratio of 1:2:1. Our
preliminary observations revealed that obese homozygotes,
unlike their lean littermates, manifest hyperphagia and
develop central (abdominal) obesity beginning at 5 weeks
of age.
Animals and experimental protocols
Ten-week-old male inbred DS/obese rats were obtained from
Japan SLC and were handled in accordance with the guide-
lines of Nagoya University Graduate School of Medicine, as
well as with the Guide for the Care and Use of Laboratory
Animals (US NIH publication no. 85-23, revised 1996). Rats
were fed normal laboratory chow containing 0.36% NaCl.
Both the diet and tap water were provided ad libitum
throughout the experimental period. At 18 weeks of age,
rats were placed in metabolic cages to collect 24-h urine
specimens and a blood sample was collected from the right
carotid artery of the rats fasted overnight. They were
subsequently killed by intraperitoneal injection of an over-
dose of sodium pentobarbital (50mg per kg body weight),
and the heart, liver, kidney, and both visceral (retroperito-
neal) and subcutaneous (inguinal) fat were removed and
subjected to analysis. Age-matched male homozygous lean
littermates of DS/obese rats, DahlS.Z-Lepr
þ/Lepr
þ (DS/lean),
served as control animals.
Physiological and metabolic analyses
Systolic blood pressure (SBP) and heart rate were measured
weekly in conscious animals by tail-cuff plethysmography
(BP-98A; Softron, Tokyo, Japan). SBP was measured five times
at each time point for each rat and the average value was
calculated. Urine volume, urinary protein and the ratio of
creatinine clearance to kidney weight or body weight were
determined by analysis of urine specimens. Creatinine
clearance was calculated using the standard formula UV/P,
where U is the urinary creatinine concentration, V is the
24-h urine volume and P is the serum creatinine concentra-
tion. Blood was collected from the right carotid artery of
rats deprived of food overnight and was centrifuged at
3000r.p.m. (1400 g) for 10min at room temperature.
The resultant serum supernatant was kept frozen at  801C
until analysis. Serum glucose and blood urea nitrogen
levels, as well as serum levels of triglyceride, total
cholesterol, low-density lipoprotein (LDL)-cholesterol, high-
density lipoprotein (HDL)-cholesterol, creatinine, aspartate
aminotransferase and alanine aminotransferase were
measured by routine enzymatic assays. The concentrations
of leptin and insulin in serum were measured using mouse/rat
enzyme-linked immunosorbent assay kits (Morinaga
Bioscience Institute, Yokohama, Japan).
Histology
Liver and kidney tissue samples were fixed in ice-cold 4%
paraformaldehyde for 48–72h, embedded in paraffin and
processed for histology as described.
12 The former was
sectioned for staining with hematoxylin–eosin and the latter
was sectioned for staining with periodic acid–Schiff solution.
Statistical analysis
Data are presented as means±s.e.m. Differences between
groups of rats at 18 weeks of age were assessed using the
Mann–Whitney U-test. The time courses of SBP or body
weight were compared between groups using two-way
repeated-measures analysis of variance. Survival rate was
analyzed by the standard Kaplan–Meier method with the
log-rank test. A P value of o0.05 was considered statistically
significant.
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Physiological analysis and survival of DS/obese rats
Body weight and visceral (4.7-fold) and subcutaneous
(5.0-fold) fat mass were increased in DS/obese rats compared
with DS/lean rats (Figure 1a, Table 1). SBP was significantly
higher in DS/obese rats than in DS/lean rats at 11 weeks of
age and thereafter (Figure 1b, Table 1). In total, 13 (65%) of
20 DS/obese rats died during the experimental period (7 from
renal failure, 2 from cerebrovascular events and 4 from
sudden cardiac death). Kaplan–Meier analysis confirmed that
the survival rate of DS/obese rats was significantly lower than
that of DS/lean rats (Figure 1c, Table 1). The ratio of left
ventricular (LV) weight to tibial length and the ratio of LV
weight to right ventricular weight, both of which are indices
of LV hypertrophy, were increased in DS/obese rats compared
with DS/lean rats (Table 1). The ratios of kidney or liver
weight to tibial length were also significantly increased in
DS/obese rats compared with DS/lean rats (Table 1). Tibial
length of DS/obese rats was significantly shorter than that of
DS/lean rats (Table 1).
Metabolic and histological analysis of DS/obese rats
The metabolic parameters of DS/obese and DS/lean rats are
summarized in Table 2. The serum leptin concentration in
DS/obese rats was 30 times that in DS/lean rats. Although
the fasting serum insulin concentration was significantly
increased in DS/obese rats compared with DS/lean rats, there
was no significant difference in the fasting serum glucose
levels between the two strains. However, in another group of
DS/obese rats (n¼6), the casual serum glucose concentration
was increased markedly (mean 309.00mg per 100ml; range
208–426mg per 100ml). These data indicate that DS/obese
rats developed type 2 diabetes mellitus and insulin resis-
tance. Serum levels of total cholesterol, LDL-cholesterol,
HDL-cholesterol and triglyceride, as well as the ratio of
LDL-cholesterol to HDL-cholesterol levels, were increased in
DS/obese rats. The serum alanine aminotransferase level was
also increased in DS/obese rats, whereas serum AST levels did
not differ significantly between the two strains. Furthermore,
DS/obese rats manifested lipid accumulation in the liver,
whereas DS/lean rats did not (Figure 2a). Blood urea
nitrogen, serum creatinine and urinary protein levels were
significantly increased, whereas the ratio of creatinine
clearance to either body or kidney weight was significantly
decreased in DS/obese rats compared with DS/lean rats.
Periodic acid–Schiff-stained micrographs revealed a grossly
normal appearance in DS/lean rats (Figure 2b, left). DS/obese
rats exhibited advanced renal lesions, such as glomerular
basement membrane thickening, mesangial matrix accumu-
lation, glycogen deposition and tubulointerstitial changes
(Figure 2b, right).
Discussion
We have shown that DS/obese rats fed a normal diet develop
obesity, as well as hypertension, dyslipidemia, insulin
resistance and type 2 diabetes mellitus. In addition, these
animals develop cardiac hypertrophy as well as renal and
liver damage, which may be responsible for their premature
death. Our results thus indicate that this rat strain may be
a suitable model of human MetS.
Leptin is an adipocyte-derived hormone that has a pivotal
role in regulation of food intake, energy expenditure, body
weight and neuroendocrine function.
14–16 The serum con-
centration of leptin was markedly increased in DS/obese rats
compared with DS/lean rats, suggesting that the obesity of
DS/obese rats is the result of leptin resistance. Hyperlep-
tinemia and leptin resistance occur in animals with diet-
induced obesity, as well as in obese humans.
17,18 We also
found that the serum concentration of insulin was increased
in DS/obese rats compared with DS/lean rats, but that serum
glucose levels did not differ between the two strains, which is
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Figure 1 Time course of body weight (a), SBP (b) and survival (c)o f
DS/obese and DS/lean rats. Data for body weight and SBP are given as
means±s.e.m. for surviving animals (n¼6 and 20 for DS/obese and DS/lean
rats, respectively, at 11 weeks and n¼6 and 7 for DS/obese and DS/lean rats,
respectively, at 18 weeks).
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former animals. Leptin suppresses insulin secretion through
both central actions and direct effects on pancreatic beta
cells.
19,20 Leptin opposes insulin resistance, in part, through
activation of AMP-activated protein kinase, which results in
a reduction in lipid deposition in insulin-sensitive tissues.
21
A lack of effective leptin signaling thus promotes the
development of insulin resistance and results in severe
obesity at an early age. Indeed, leptin resistance has been
shown to induce hyperinsulinemia and insulin resistance in
both humans and animals.
22,23 Furthermore, there is an
interdependent relation between insulin sensitivity and salt
sensitivity of blood pressure in DS rats.
24 DS/obese rats may
therefore develop insulin resistance as a result of a failure to
respond to leptin (because of the mutation in the leptin
receptor) and the increased salt sensitivity of blood pressure.
Leptin regulates blood pressure through the sympathetic
nervous system.
25 Blood pressure in genetically obese
animals with leptin resistance, including obese Zucker rats,
has been shown to be reduced or at least not elevated
compared with that in their lean littermates.
26,27 In the present
study, DS/obese rats fed a normal diet manifested increases in
both SBP and body weight compared with DS/lean rats at
11 weeks of age and thereafter. It is possible that the presence of
the fa allele of Lepr is associated with increased salt sensitivity
of blood pressure. Whereas SBP was relatively constant in
DS/lean rats during the entire experimental period, it increased
progressively, together with body weight, in DS/obese rats.
Given that the ratios of both LV weight to tibial length and LV
weight to right ventricular weight were significantly increased
in DS/obese rats, LV hypertrophy was induced in association
with hypertension. Tibial length was significantly shorter in
DS/obese rats than in DS/lean ra t s .G i v e nt h a tl e p t i nc o n t r i -
butes to the central regulation of bone metabolism,
28 the
growth of bone may be inhibited in DS/obese rats because of
the leptin receptor mutation.
Table 1 Physiological parameters of DS/lean and DS/obese rats at 18 weeks of age
Parameter DS/lean DS/obese P
Body weight (g) 443.75±21.62 536.92±6.98 0.0072
Tibial length (mm) 40.27±0.24 36.47±0.12 0.0036
SBP (mmHg) 137.7±03.04 210.62±2.54 0.0047
Heart rate (beatsmin
 1) 417.32±13.71 400.73±15.40 0.1792
Heart weight/tibial length (mg/mm) 32.71±1.43 42.22±0.29 0.0019
LV weight/tibial length (mg/mm) 24.22±1.02 32.69±0.37 0.0036
LV weight/RV weight 4.21±0.05 4.74±0.12 0.0301
Atrial weight/tibial length (mg/mm) 2.06±0.23 2.55±0.14 0.0896
Kidney weight/tibial length (mg/mm) 78.41±6.36 128.89±3.79 0.0025
Liver weight/tibial length (mg/mm) 312.19±25.29 600.11±42.14 0.0021
Visceral fat weight/tibial length (mg/mm) 178.02±31.55 839.28±33.00 0.0036
Subcutaneous fat weight/tibial length (mg/mm) 158.77±27.34 795.02±41.33 0.0036
Survival (%) 100 35 0.0423
Abbreviations: DS, Dahl salt-sensitive; LV, left ventricular; RV, right ventricular; SBP, systolic blood pressure. With the exception of survival rate, data are given as
means±s.e.m. for surviving animals (n¼6 and 7 for DS/lean and DS/obese rats, respectively).
Table 2 Metabolic parameters of DS/lean and DS/obese rats at 18 weeks of age
Parameter DS/lean DS/obese P
Leptin (ngml
 1) 1.67±0.37 53.97±2.34 0.0005
Glucose (mg per 100ml) 124.50±6.40 136.33±5.27 0.2864
Insulin (ngml
 1) 0.55±0.29 3.18±1.39 0.0209
Triglyceride (mg per 100ml) 102.25±25.98 1559.93±353.89 0.0029
Total cholesterol (mg per 100ml) 116.25±11.59 371.14±39.21 0.0029
LDL-cholesterol (mg per 100ml) 24.00±2.94 73.85±7.15 0.0046
HDL-cholesterol (mg per 100ml) 26.75±1.11 50.14±2.30 0.0029
LDL-cholesterol/HDL-cholesterol 0.89±009 1.59±0.15 0.0257
AST (Ul
 1)5 7 . 0 0 ±1.52 67.33±4.67 0.1213
ALT (Ul
 1)2 4 . 6 7 ±0.88 39.25±2.63 0.0087
Blood urea nitrogen (mg per 100ml) 19.98±1.86 76.21±13.56 0.0029
Creatinine (mg per 100ml) 0.32±0.03 1.09±0.19 0.0029
Urinary protein (mgday
 1) 336.29±19.58 735.52±93.97 0.0143
Ccr (mlmin
–1 per g kidney weight) 1.25±0.12 0.20±0.03 0.0082
Ccr (mlmin
–1 per 100g body weight) 0.91±0.06 0.18±0.02 0.0082
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; Ccr, creatinine clearance; DS, Dahl salt-sensitive; HDL, high-density lipoprotein;
LDL, low-density lipoprotein. Analytes were measured in serum unless indicated otherwise. Data are given as means±s.e.m. for surviving animals (n¼6 and 7 for
DS/lean and DS/obese rats, respectively).
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HDL-cholesterol and triglyceride, as well as the ratio of
LDL-cholesterol to HDL-cholesterol concentrations, were
significantly increased in DS/obese rats compared with
DS/lean rats. The serum of most DS/obese rats was also
milky in appearance as a result of their triglyceride and total
cholesterol levels being increased 15- and 3-fold, respec-
tively. The marked increase in serum alanine amino-
transferase level and lipid accumulation in the liver of
DS/obese rats is indicative of fat-induced liver damage.
Pronounced renal damage was also apparent in these
animals, as revealed by their proteinuria and a decrease in
creatinine clearance and by abnormal periodic acid–Schiff
staining. Several metabolic, functional and structural renal
changes in diabetic rodents have fundamental similarities
to those occurring in diabetic patients.
29 These diabetic
rodents develop renal enlargement, glomerular hypertrophy
and renal hyperfiltration within weeks after diabetes debut
and, subsequently, increased albumin excretion rate,
glomerular extracellular matrix accumulation, increased
glomerular basement membrane thickness and mesangial
proliferation within months. Moreover, tubulointerstitial
fibrosis in diabetes mellitus is an important patho-
logical feature of advanced diabetic nephropathy, particu-
larly in those patients with associated renal insufficiency.
30
Thus, the renal pathological findings observed in DS/obese
rats were in good agreement with those in overt diabetic
nephropathy.
Several rat strains could be potentially used to study MetS.
3
Although Zucker fatty rats are a widely used model of insulin
resistance and type 2 diabetes mellitus, they cannot be
considered as a clear experimental model of hypertension.
The JCR:LA-corpulent rat, if homozygous for the cp gene,
exhibits signs and symptoms characteristic of MetS, but they
are not hypertensive.
31 The spontaneously hypertensive rats
(SHRs), a well-known experimental model of hypertension,
have also been proposed as a model of insulin resistance. In
the background of SHRs, different strains of corpulent SHRs,
such as obese SHRs/Koletsky rats, SHRs/N-corpulent rats and
SHRs/NDmc-corpulent rats, seem to be more appropriate to
study MetS than the SHRs. However, these strains slowly
develop moderate hypertension with a normal diet and
therefore require a long period to exhibit the characteristics
of cardiovascular disease.
32 In contrast, DS/obese rats used
in the present study become markedly hypertensive even
with a normal diet, reflecting increased salt sensitivity of
blood pressure, and cause cardiovascular complications and
premature death within a relatively short period.
In conclusion, our results show that DS/obese rats fed
a normal diet develop obesity as well as hypertension,
dyslipidemia and insulin resistance. The phenotype of
DS/obese rats is thus similar to that of humans with MetS.
The newly established DS/obese rat may therefore be a good
animal model of human MetS, and further studies of this
model should improve our understanding of the interaction
between metabolic and cardiovascular phenotypes in MetS.
DS/lean DS/obese
Figure 2 Histology of the liver and kidney of DS/lean and DS/obese rats at 18 weeks of age. Sections of the liver were stained with hematoxylin–eosin (a) and those
of the kidney were stained with periodic acid–Schiff (PAS) solution (b). Scale bar, 100mm.
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